A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies-Reference-Cited by-同舟云学术

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies

Published:2010-02-18 Issue:6 Volume:66 Page:1079-1085
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Paik Paul K.,Rudin Charles M.,Brown Andrew,Rizvi Naiyer A.,Takebe Naoko,Travis William,James Leonard,Ginsberg Michelle S.,Juergens Rosalyn,Markus Susan,Tyson Leslie,Subzwari Sara,Kris Mark G.,Krug Lee M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-010-1265-5.pdf

Reference27 articles.

1. Hu W, Kavanagh JJ (2003) Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4:721–729

2. Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26:1324–1337

3. Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5:876–885

4. GeminX I (2006) Investigator’s brochure GX15-070MS. Malvern, PA

5. Perez-Galan P, Roue G, Villamor N (2006) The small molecule pan-Bcl-2 inhibitor GX15-070 induces apoptosis in vitro in mantle cell lymphoma (MCL) cells and exhibits a synergistic effect in combination with the proteasome inhibitor bortezomib, AACR, pp A575

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationships of Prodiginins Mechanisms and Molecular Structures to their Antiproliferative Effects;Anti-Cancer Agents in Medicinal Chemistry;2024-08-07

2. Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug;Frontiers in Chemistry;2023-09-07

3. Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors;Cell Death & Disease;2022-04-28

4. Therapeutics targeting BCL2 family proteins;Mechanisms of Cell Death and Opportunities for Therapeutic Development;2022

5. A decision process for drug discovery in retinoblastoma;Investigational New Drugs;2020-11-16